Stoke Therapeutics (STOK) Azione Prezzo
Stoke Therapeutics Prezzo
Negli ultimi 4 anni Stoke Therapeutics ha aumentato il fatturato del 180,0% all'anno, raggiungendo 184,42 Mio. USD. Per Stoke Therapeutics, il margine netto del -3,7% risulta in aumento rispetto al -2823,7% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Stoke Therapeutics è 44,00 USD, circa il 58,8% sopra il prezzo attuale di mercato. Su 20 analisti, 19 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Stoke Therapeutics Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Stoke Therapeutics Azione e analisi azionaria
Domande frequenti sull'azione Stoke Therapeutics
The business model of Stoke Therapeutics Inc revolves around developing innovative RNA-targeted therapeutics to treat severe genetic diseases. By focusing on addressing the underlying causes of diseases, Stoke Therapeutics aims to provide long-term solutions for patients. Its proprietary technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO), enables the modulation of gene expression levels to restore the production of functional proteins. Stoke Therapeutics collaborates with industry partners and utilizes its expertise in RNA biology to advance potential therapies for a range of genetic disorders. Through its business model, the company aims to improve the lives of patients with severe genetic diseases through innovative and targeted treatments.
Stoke Therapeutics Inc is primarily active in the biotechnology industry.
The main competitors of Stoke Therapeutics Inc in the market include companies such as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Akcea Therapeutics.
Stoke Therapeutics Inc is a biotechnology company founded in 2018, based in Bedford, Massachusetts. Focused on addressing the underlying causes of severe genetic diseases, Stoke Therapeutics utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. This platform enables the development of antisense oligonucleotide (ASO) therapies to increase protein levels and restore gene expression. By targeting RNA instead of DNA, Stoke Therapeutics aims to treat a range of genetic disorders, including genetic epilepsies, genetic conditions affecting the central nervous system, and other rare diseases. Their innovative approach holds promise for patients with limited treatment options, making Stoke Therapeutics a key player in the biotech industry.
Stoke Therapeutics Inc has achieved several significant milestones. The company successfully completed its initial public offering in June 2019, raising approximately $142 million in net proceeds. In January 2020, Stoke Therapeutics received the FDA's rare pediatric disease designation for its lead product candidate, STK-001, which aims to treat Dravet syndrome, a severe form of epilepsy. Furthermore, the company initiated a Phase 1/2a clinical trial of STK-001 in October 2020. Stoke Therapeutics continues to make progress in advancing its pipeline and developing innovative therapies for genetic diseases.
Stoke Therapeutics Inc is primarily present in the United States.
Stoke Therapeutics Inc represents values of innovation, collaboration, and commitment to patients. The company's corporate philosophy revolves around developing transformative treatments for severe genetic diseases. Stoke is dedicated to harnessing the power of RNA biology to address the underlying cause of such diseases. By prioritizing scientific advancement and partnerships, Stoke Therapeutics Inc aims to make a positive impact on patients' lives. The company strives to excel in translating cutting-edge research into therapeutic breakthroughs, offering hope and delivering long-term value for patients, their families, and the healthcare community.
Gli analisti fissano attualmente un prezzo obiettivo medio di 47,33 USD per l’azione Stoke Therapeutics (mediana: 44,00 USD), pari a +70,8 % rispetto all’ultimo prezzo. Il consenso si basa su 20 giudizi di analisti.
20 analisti valutano attualmente l’azione Stoke Therapeutics: 19 raccomandano l’acquisto, 1 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Stoke Therapeutics ricavi pari a 34,39 Mio. USD e un utile per azione di -3,82 USD.
Convertita al tasso di cambio attuale, l’azione Stoke Therapeutics quota 24,73 EUR (27,71 USD).
L’azione Stoke Therapeutics (STOK) è quotata su 3 borse, tra cui: NASDAQ (STOK), Frankfurt (0GT.F), München (0GT.MU).
Stoke Therapeutics Inc. is a biopharmaceutical company focused on developing technologies and therapies for the treatment of rare genetic diseases. Their business model is based on the application of a novel technology platform called Targeted Augmentation of Nuclear Gene Output (TANGO), which allows for the increase or decrease of gene expression. They aim to achieve therapeutic effects by specifically augmenting gene expression through their TANGO platform, which involves developing RNA molecules known as antisense oligonucleotides (ASOs) to modulate gene expression. Stoke Therapeutics has multiple products in various stages of development, with their most advanced candidate, STK-001, targeting the treatment of autosomal recessive spinobulbar muscular atrophy (SMA). They are also working on therapies for other rare diseases such as autosomal dominant optic atrophy (ADOA) and Dravet syndrome. Overall, Stoke Therapeutics focuses on developing RNA-based therapeutics for rare genetic diseases caused by loss-of-function mutations.
Il attesa fatturato di Stoke Therapeutics ammonta a 34,39 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Stoke Therapeutics ammonta a -223,21 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Stoke Therapeutics è attualmente -7,25. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Stoke Therapeutics.
Il rapporto prezzo/fatturato (P/S) di Stoke Therapeutics è attualmente 47,05. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Stoke Therapeutics.
Il Quality Score AlleAktien per Stoke Therapeutics è 4/10.
L'ISIN di Stoke Therapeutics è US86150R1077. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Stoke Therapeutics è A2PLTL. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Stoke Therapeutics è STOK. Con questo simbolo di borsa vengono negoziate le azioni Stoke Therapeutics in borsa.
Azione Stoke Therapeutics
Gruppo di pari di Stoke Therapeutics
Stoke Therapeutics Ticker
Stoke Therapeutics FIGI
Altre metriche e analisi di Stoke Therapeutics in Deep Dive.
La nostra analisi azionaria dell'azione Stoke Therapeutics include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Stoke Therapeutics. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: